As a new-type foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has built a "1+2+3+4=1" service system and can supply original factory sources of Beta Galactosidase from multiple well-known brands.
As a research and development-oriented foreign trade enterprise, HiSiaddi is not limited to promoting only its partner brands. We objectively analyze multiple high-market-share domestic and international leading brands and share their latest major technological process advancements and breakthroughs to provide purchasers with authentic, timely and valuable market intelligence.
If you require more comprehensive and valuable market information on Beta Galactosidase, please contact HiSiaddi customer service.
1. Breakthrough details: Directed protein evolution of Aspergillus oryzae strains delivers a 32% faster lactose hydrolysis rate in liquid cow’s milk. At identical dosage, maximum lactose hydrolysis rate rises from 92% to 99.1%, compressing the original 8-hour hydrolysis stage to 5.2 hours with a corresponding 18% reduction in Beta Galactosidase consumption per ton of finished product. Optimized for in-situ hydrolysis in 2–12°C low-temperature fresh milk, retaining 76% baseline enzyme activity at low temperatures (traditional variants retain only 38%).
2. Benefits for purchasers: Daily single-unit production capacity of dairy lines rises by 28%, raw material tonnage costs drop by 16%, and capital expenditure on additional hydrolysis holding tanks is eliminated.
3. End-consumer benefits: Residual lactose in lactose-free fresh milk falls below 0.2g/100mL to fully eliminate bloating and diarrhea discomfort, with a 5-day extended shelf life for finished products.
1. Breakthrough details: Optimized yeast expression systems widen the optimal reaction temperature range to 38–58°C, retaining 79% enzyme activity after 55°C instantaneous pasteurization (old generations retain only 52%). Heat energy consumption during full hydrolysis drops by 15% with significantly reduced steam demand per unit output. Side transglycosylation reactions are controlled to stabilize GOS production at 31% with a 62% reduction in miscellaneous sugar impurities.
2. Benefits for purchasers: Energy costs for heat-treated yogurt and infant formula powder manufacturing fall by 13%, eliminating segmented temperature control requirements and simplifying production workflows.
3. End-consumer benefits: Lactose-free infant formula develops no burnt off-flavors, removing the need for extra sweeteners to mask hydrolysis by-product tastes.
1. Breakthrough details: Modified enzyme substrate binding sites eliminate the traditional limitation of exclusive cow’s milk compatibility, enabling simultaneous hydrolysis of trace endogenous lactose and added dairy lactose in oat milk and soy milk. Hydrolysis efficiency for plant-based beverage systems rises by 27% versus universal enzymes, with ≤8% enzyme activity fluctuation across the full pH 3.8–7.4 range (standard enzymes fluctuate over 35%).
2. Benefits for purchasers: Plant milk manufacturers cover dairy-containing and pure plant product lines with a single enzyme variant, reducing multi-specification raw material inventory and cutting warehousing costs by 22%.
3. End-consumer benefits: Mixed plant-dairy beverages are fully lactose-free to prevent bloating, catering to both vegan and lactose-intolerant consumer groups.
1. Breakthrough details: Gene-edited strain optimization enables complete lactose hydrolysis within the 4-hour yogurt fermentation cycle (traditional workflows require separate 6–8 hour pre-hydrolysis prior to fermentation). 83% enzyme activity retention at 42°C fermentation temperature resolves premature deactivation under high fermentation heat, stabilizing residual lactose below 0.18g/100mL in fermented dairy products.
2. Benefits for purchasers: Yogurt production lines eliminate pre-hydrolysis stages with zero production line renovation costs and a 35% higher production turnover efficiency.
3. End-consumer benefits: Shelf-stable yogurt and kefir beverages are lactose-free with uniform sweet-sour flavor and no post-fermentation sourness.
1. Breakthrough details: Nano-encapsulation modification delivers stable activity at pH 2.2 strong gastric acid environments, while standard neutral Beta Galactosidase loses over 70% activity under gastric conditions. Lactose decomposition utilization in livestock feed rises from 59% to 89%, preventing intestinal gas fermentation from excess lactose.
2. Benefits for purchasers: Feed manufacturers reduce wasted whey powder, boosting whey raw material utilization by 25% and cutting formula costs by 8%.
3. End-consumer benefits: Diarrhea rates in young livestock fall by 41%, with a 12% faster growth rate in young cattle, sheep and goats.
1. Breakthrough details: CRISPR site-directed modification of Aspergillus niger engineered strains boosts cell density in 50m³ fermenters by 42%. Production costs per ten thousand ALU Beta Galactosidase drop from 142.6 CNY to 112.5 CNY (-21%). Food-grade solid powder enzyme activity rises from standard 100,000 ALU/g to 135,000 ALU/g, fully compliant with international ALU testing standards and certified under EU EC1332 food enzyme regulations across all product lines.
2. Benefits for purchasers: Unit pricing for equivalent enzyme activity is 24% lower than imported alternatives, enabling direct cost reduction for small and medium European/American dairy manufacturers switching to domestic raw materials.
3. End-consumer benefits: Infant oral drop Beta Galactosidase requires 30% less dosage, simplifying product formulations and eliminating auxiliary allergen risks.
1. Breakthrough details: Mass production of chitosan-modified immobilization carrier technology delivers 93% retained enzyme activity at 75°C with 12 continuous catalytic cycles (free enzymes are single-use only). Recoverable via filtration post-hydrolysis with <0.5% residual enzyme in wastewater, complying with EU wastewater discharge regulations. Optimized for continuous large-scale lactose-free milk raw liquid production lines.
2. Benefits for purchasers: Annual enzyme consumable expenditure for large dairy factories drops by 65%, alongside reduced solid waste treatment fees.
3. End-consumer benefits: Retail prices for mass-produced lactose-free liquid milk can be reduced by 7%, strengthening end-product market competitiveness.
1. Breakthrough details: Directed evolution generates dual-functional mutant enzymes that hydrolyze 79% of lactose into monosaccharides under 5–10°C raw milk processing conditions while simultaneously producing 32g/L GOS oligosaccharides (traditional enzymes yield only 24.8g/L GOS). Single-step processing delivers dual-value raw dairy materials with low lactose and high prebiotic content, eliminating separate GOS addition workflows.
2. Benefits for purchasers: Functional dairy manufacturers eliminate external GOS raw material procurement, cutting formula ingredient costs by 19%.
3. End-consumer benefits: Finished dairy products naturally contain prebiotics to improve intestinal flora, supporting a 15% higher premium pricing capacity.
1. Breakthrough details: Small-molecule glycerol encapsulation modification extends ambient light-protected shelf life of oral drops from 6 months to 14 months. 68% enzyme activity retention at human gastric pH 2.5 (older domestic variants retain only 32%), enabling simultaneous administration with breast milk or formula without separate feeding intervals. All eight major allergen groups are removed from formulations, with US FDA infant dietary supplement filing approval.
2. Benefits for purchasers: Storage losses for cross-border maternal and infant distributors fall by 70%, eliminating cold-chain requirements for global ambient transport and cutting cross-border shipping costs by 33%.
3. End-consumer benefits: Simplified feeding for lactose-intolerant infants without breast milk cessation, with accelerated relief from infant diarrhea.
1. Breakthrough details: Mass production of membrane separation + chromatographic purification technology cuts miscellaneous protein impurities in IVD kit-specific β-galactosidase from 0.12% to 0.03%, meeting dual standards of USP US Pharmacopoeia and EP European Pharmacopoeia. Enhanced enzyme labeling stability extends diagnostic kit shelf life from 12 to 18 months, optimized for biochemical reagent applications in early Alzheimer’s screening.
2. Benefits for purchasers: Overseas IVD reagent manufacturers avoid expensive imported reagent-grade enzymes, slashing raw material procurement costs by 30%.
3. End-consumer benefits: Diagnostic error rates for medical test kits fall by 52%, delivering drastically improved detection accuracy.
1. Purchaser-side: All leading domestic and international brands deliver reduced enzyme consumption, lower energy use and decreased warehousing/logistics costs. Average unit consumption costs for Beta Galactosidase fell 12%–22% industry-wide in 2025, with high-end domestic Beta Galactosidase steadily replacing imported equivalents.
2. End-product side: Five major downstream sectors (dairy products, infant complementary food, functional food, feed, diagnostic reagents) enjoy upgraded finished product quality, optimized formulations and lower retail pricing, with a universal 10%–25% rise in market penetration for purchasers’ end products.
If you require more comprehensive and valuable market information on Beta Galactosidase, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
